ARTICLE | Clinical News
Bavituximab regulatory update
January 13, 2014 8:00 AM UTC
Peregrine said FDA granted Fast Track designation to bavituximab for second-line treatment of non-small cell lung cancer (NSCLC). The chimeric mAb against phosphatidylserine is in the Phase III SUNRI...